HRP20191486T2 - Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze - Google Patents

Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze Download PDF

Info

Publication number
HRP20191486T2
HRP20191486T2 HRP20191486TT HRP20191486T HRP20191486T2 HR P20191486 T2 HRP20191486 T2 HR P20191486T2 HR P20191486T T HRP20191486T T HR P20191486TT HR P20191486 T HRP20191486 T HR P20191486T HR P20191486 T2 HRP20191486 T2 HR P20191486T2
Authority
HR
Croatia
Prior art keywords
fluoro
methoxy
chloro
hydroxypiperidin
fluorophenyl
Prior art date
Application number
HRP20191486TT
Other languages
English (en)
Croatian (hr)
Inventor
Hiroshi Shimizu
Yoshikazu Kawano
Shunpei Ishikawa
Yukitaka UEMATSU
Toshio Shinohara
Motohiro Itotani
Yoshikazu Haraguchi
Isao Takemura
Atsunori KANESHIGE
Yuya NAKAI
Norimitsu Hariguchi
Yohei Hayashi
Makoto Matsumoto
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54105947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191486(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of HRP20191486T1 publication Critical patent/HRP20191486T1/hr
Publication of HRP20191486T2 publication Critical patent/HRP20191486T2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/227Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
HRP20191486TT 2014-08-28 2015-08-28 Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze HRP20191486T2 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014174528 2014-08-28
EP15763096.3A EP3186240B9 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis
PCT/JP2015/004371 WO2016031255A1 (en) 2014-08-28 2015-08-28 Heterobicyclic compounds and their use for the treatment of tuberculosis

Publications (2)

Publication Number Publication Date
HRP20191486T1 HRP20191486T1 (hr) 2019-11-15
HRP20191486T2 true HRP20191486T2 (hr) 2021-09-17

Family

ID=54105947

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191486TT HRP20191486T2 (hr) 2014-08-28 2015-08-28 Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze

Country Status (29)

Country Link
US (2) US10053446B2 (enExample)
EP (1) EP3186240B9 (enExample)
JP (1) JP6625612B2 (enExample)
KR (1) KR102418413B1 (enExample)
CN (1) CN106795117B (enExample)
AP (1) AP2017009788A0 (enExample)
AR (1) AR101704A1 (enExample)
AU (1) AU2015307873B2 (enExample)
BR (1) BR112017003231B1 (enExample)
CA (1) CA2959478C (enExample)
CY (1) CY1122286T1 (enExample)
DK (1) DK3186240T3 (enExample)
EA (1) EA038414B1 (enExample)
ES (1) ES2743788T3 (enExample)
HR (1) HRP20191486T2 (enExample)
HU (1) HUE045025T2 (enExample)
IL (1) IL250484B (enExample)
LT (1) LT3186240T (enExample)
MX (1) MX2017002312A (enExample)
MY (1) MY189098A (enExample)
NZ (1) NZ729064A (enExample)
PH (1) PH12017500290B1 (enExample)
PL (1) PL3186240T3 (enExample)
PT (1) PT3186240T (enExample)
SG (1) SG11201700882XA (enExample)
SI (1) SI3186240T1 (enExample)
TW (1) TWI687409B (enExample)
WO (1) WO2016031255A1 (enExample)
ZA (1) ZA201700916B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
JP6905506B2 (ja) * 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体
KR20210021042A (ko) 2018-06-15 2021-02-24 카딜라 핼쓰캐어 리미티드 포유동물 감염 치료를 위한 신규한 화합물
JP2023085582A (ja) * 2020-05-11 2023-06-21 大塚製薬株式会社 ジヒドロキノリノン化合物の共結晶
WO2022039506A1 (ko) * 2020-08-19 2022-02-24 주식회사 미토이뮨테라퓨틱스 Mabc-r 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
CN116102537B (zh) * 2021-11-10 2024-10-01 四川大学 一种喹啉酮类衍生物及其制备方法和用途
CN116589448B (zh) * 2023-04-24 2025-10-28 西南交通大学 一种3,4-二氢喹啉酮衍生物及其应用
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Quabodepistat含有組成物
WO2025183016A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Quabodepistat含有組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
TWI347946B (en) 2002-10-11 2011-09-01 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
AU2004285811B2 (en) * 2003-10-31 2008-06-12 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 2,3−ジヒドロイミダゾ[2,1−b]オキサゾ−ル化合物
ZA200602184B (en) * 2003-10-31 2007-10-31 Otsuka Pharma Co Ltd 2,3-dihydro-6-nitroimidazo (2,1-B) oxazole compounds for the treatment of tuberculosis
PL2489659T3 (pl) * 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
EP1988077A4 (en) 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
GB0812648D0 (en) * 2008-07-10 2008-08-20 Prosidion Ltd Compounds
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
RU2540860C2 (ru) 2009-07-31 2015-02-10 Глоубал Элаенс Фор Тб Драг Дивелопмент Нитроимидазооксазиновые и нитроимидазооксазольные аналоги и их применение
JP5916739B2 (ja) 2011-04-15 2016-05-11 大塚製薬株式会社 6,7−ジヒドロイミダゾ[2,1−b][1,3]オキサジン化合物
AR101704A1 (es) * 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
JP6905506B2 (ja) * 2016-02-26 2021-07-21 大塚製薬株式会社 ピペリジン誘導体

Also Published As

Publication number Publication date
CN106795117A (zh) 2017-05-31
MY189098A (en) 2022-01-25
PH12017500290B1 (en) 2023-07-19
CY1122286T1 (el) 2021-01-27
KR20170043644A (ko) 2017-04-21
PT3186240T (pt) 2019-09-06
IL250484B (en) 2020-04-30
LT3186240T (lt) 2019-09-10
US20180312488A1 (en) 2018-11-01
AR101704A1 (es) 2017-01-04
US20170253576A1 (en) 2017-09-07
EP3186240A1 (en) 2017-07-05
EA038414B1 (ru) 2021-08-25
ZA201700916B (en) 2019-06-26
TWI687409B (zh) 2020-03-11
BR112017003231B1 (pt) 2022-10-11
WO2016031255A1 (en) 2016-03-03
CA2959478C (en) 2023-09-26
AU2015307873A1 (en) 2017-03-09
ES2743788T3 (es) 2020-02-20
EP3186240B9 (en) 2019-12-04
DK3186240T3 (da) 2019-08-26
HRP20191486T1 (hr) 2019-11-15
HUE045025T2 (hu) 2019-12-30
JP6625612B2 (ja) 2019-12-25
TW201609658A (zh) 2016-03-16
IL250484A0 (en) 2017-03-30
PL3186240T3 (pl) 2020-03-31
SG11201700882XA (en) 2017-03-30
BR112017003231A2 (pt) 2017-11-28
PH12017500290A1 (en) 2017-06-28
CA2959478A1 (en) 2016-03-03
SI3186240T1 (sl) 2019-10-30
CN106795117B (zh) 2020-06-26
NZ729064A (en) 2022-09-30
KR102418413B1 (ko) 2022-07-06
EA201790464A1 (ru) 2017-06-30
US10053446B2 (en) 2018-08-21
AP2017009788A0 (en) 2017-02-28
US10464926B2 (en) 2019-11-05
AU2015307873B2 (en) 2020-01-16
JP2017525697A (ja) 2017-09-07
EP3186240B1 (en) 2019-06-12
MX2017002312A (es) 2017-05-08

Similar Documents

Publication Publication Date Title
HRP20191486T2 (hr) Heterobiciklički spojevi i njihova uporaba za liječenje tuberkuloze
ES2527467T3 (es) Nuevas bencenosulfonamidas como bloqueantes de canales de calcio
JP2011511790A5 (enExample)
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
AR049139A1 (es) Compuestos derivados de benzamidas n - heterociclil - sustituidas como activadores de la glucoquinasa (glk), metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso como medicamento en el tratamiento de la diabetes tipo ii.
MA34964B1 (fr) Dérivés de pipéridine pontés
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
CA2682329A1 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
AR049739A1 (es) Derivados de aril-piridina
EP1724262A4 (en) 1- (2H) -ISOCHINOLONDERIVAT
PH12013500773A1 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
CO6220970A2 (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos
MA29398B1 (fr) Derives de coumarine substituee par un thiadiazole et leur utilisation en tant qu'inhibiteur de biosynthese de leucotriene.
AR081426A1 (es) Derivados de pirazol inhibidores del receptor sigma
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR060535A1 (es) Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina
PE20150774A1 (es) Aminoquinolinas como inhibidores de cinasa
DK2868660T3 (da) Anti-tumoreffekt-potentiator omfattende en imidazooxazin-forbindelse
AR070635A1 (es) DERIVADOS DE PIRIDOPIRAZINONA QUE ESTIMULAN LA SECRECIoN DE INSULINA, MÉTODOS PARA OBTENERLOS, SU USO EN EL TRATAMIENTO DE LA DIABETES Y COMPOSICIONES FARMACEUTICAS.
DOP2010000226A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos
AR071925A1 (es) Malonamidas como antagonistas de orexina
AR084515A1 (es) Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
HRP20080227T3 (hr) Pirolidinski derivati kao ligandi histaminskih receptora
NO20090214L (no) Proteinkinase C aktivitetsforsterker inneholdende alkyleterderivat eller et salt av denne